Financial reports
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
10-K
2022 FY
Annual report
14 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
30 Mar 22
10-Q
2021 Q3
Quarterly report
4 Nov 21
Current reports
8-K
Termination of a Material Definitive Agreement
24 Jan 24
8-K
Other Events
22 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
19 Dec 23
8-K
Other Events
8 Dec 23
8-K
Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH
30 Nov 23
8-K
Other Events
21 Nov 23
8-K
Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments
13 Nov 23
8-K
Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-of-concept Study of OTL-203 in MPS-IH at ESGCT 2023
26 Oct 23
8-K
Kyowa Kirin to Acquire Orchard Therapeutics
5 Oct 23
8-K
Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in MLD and Receives Priority Review
18 Sep 23
Registration and prospectus
15-12G
Securities registration termination
5 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Jan 24
POS AM
Prospectus update (post-effective amendment)
24 Jan 24
POS AM
Prospectus update (post-effective amendment)
24 Jan 24
25-NSE
Exchange delisting
24 Jan 24
Proxies
DEFA14A
Additional proxy soliciting materials
8 Dec 23
DEFA14A
Additional proxy soliciting materials
30 Nov 23
DEFA14A
Additional proxy soliciting materials
21 Nov 23
DEFM14A
Proxy related to merger
16 Nov 23
PREM14A
Preliminary proxy related to merger
3 Nov 23
DEFA14A
Additional proxy soliciting materials
17 Oct 23
DEFA14C
Additional information
5 Oct 23
DEFA14C
Additional information
5 Oct 23
DEFA14C
Additional information
5 Oct 23
DEFA14C
Additional information
5 Oct 23
Other
EFFECT
Notice of effectiveness
31 Jan 24
EFFECT
Notice of effectiveness
31 Jan 24
EFFECT
Notice of effectiveness
22 Aug 23
CORRESP
Correspondence with SEC
17 Aug 23
UPLOAD
Letter from SEC
16 Aug 23
EFFECT
Notice of effectiveness
2 May 22
CORRESP
Correspondence with SEC
27 Apr 22
UPLOAD
Letter from SEC
5 Apr 22
EFFECT
Notice of effectiveness
6 Jun 19
CORRESP
Correspondence with SEC
3 Jun 19
Ownership
SC 13G
Blue Owl Capital Holdings LP
14 Feb 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
FMR LLC
12 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G/A
Beryl Capital Management LLC
8 Feb 24
4
Alicia Secor
24 Jan 24
4
JAMES A GERAGHTY
24 Jan 24
4
FRANK E THOMAS
24 Jan 24
4
Charles A Rowland Jr
24 Jan 24
4
Joanne T. Beck
24 Jan 24